Company Overview

Bicycle Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of a novel class of therapeutics known as Bicycle® peptides. The company operates primarily within the biopharmaceutical and oncology industries, targeting diseases where traditional small molecules or biologics face limitations in specificity, tissue penetration, or safety. Its core revenue drivers are research and development activities, milestone payments, and collaboration revenues, as it does not yet generate product sales.

The company’s proprietary Bicycle® peptide platform is designed to combine the selectivity of antibodies with the favorable pharmacokinetics of small molecules, which the company positions as a competitive advantage in oncology drug development. Bicycle Therapeutics was founded in 2009 and has evolved from an early-stage research company into a publicly listed clinical-stage enterprise, completing its initial public offering on the Nasdaq in 2019. Its pipeline has progressively advanced into clinical development, with a strategic emphasis on oncology targets.

Business Operations

Bicycle Therapeutics operates as a single-reportable segment focused on the research, development, and advancement of therapeutic candidates derived from its Bicycle® peptide technology. The company generates revenue primarily through collaborative research agreements, upfront payments, and milestone-based compensation from strategic partners, alongside equity financing to support ongoing clinical trials.

Operationally, the company maintains integrated discovery and development capabilities, controlling its proprietary peptide screening and optimization technologies. It conducts both domestic and international operations through Bicycle Therapeutics plc and its wholly owned subsidiary Bicycle Therapeutics, Inc. The company has established strategic collaborations with large pharmaceutical partners to advance select programs, while retaining internal ownership of key oncology assets. Details of certain partnerships and financial terms are limited to disclosures in public filings.

Strategic Position & Investments

The strategic direction of Bicycle Therapeutics centers on advancing a focused oncology pipeline while leveraging partnerships to validate and monetize its platform. Growth initiatives include the clinical progression of internally developed candidates and selective out-licensing or co-development arrangements to offset development risk and capital requirements. The company has invested heavily in expanding its discovery engine and clinical development infrastructure rather than pursuing broad-based acquisitions.

Bicycle Therapeutics has not reported a large portfolio of acquired subsidiaries, instead prioritizing organic development and targeted collaborations. Its emerging technology focus remains tightly aligned with next-generation targeted therapeutics, including toxin-conjugated and immune-modulating Bicycle® molecules. Where disclosures on specific investment outcomes or partner-led programs are limited, data is inconclusive based on available public sources.

Geographic Footprint

The company is headquartered in Cambridge, United Kingdom, a major global biotechnology hub, and maintains a significant operational presence in the United States, particularly in Massachusetts, to support clinical development and corporate functions. This transatlantic structure supports access to scientific talent, regulatory engagement, and capital markets.

Bicycle Therapeutics’ clinical and research activities have an international reach through global clinical trial sites and partnerships with multinational pharmaceutical companies. While it does not maintain manufacturing operations at commercial scale, its international footprint reflects its strategy of operating as a globally oriented clinical-stage biotechnology company.

Leadership & Governance

Bicycle Therapeutics was co-founded by Sir Gregory Winter, whose work in protein engineering helped shape the company’s scientific foundation, and Christian Heinis, who contributed to the development of the Bicycle® peptide technology. The leadership team emphasizes scientific rigor, disciplined capital allocation, and strategic partnerships as core elements of its governance philosophy.

Key members of the executive leadership include:

• Kevin Lee – Chief Executive Officer
• Andrew Skimming – Chief Financial Officer
• Nicolas Gaudreault – Chief Scientific Officer
• Christian Heinis – Chief Technology Officer

The board and management team collectively bring experience across biotechnology research, clinical development, and public company governance, aligning the company’s long-term strategy with shareholder and patient interests.